SR 11302

Research use only, not for human use.

SR 11302 is an inhibitor of activator protein-1 (AP-1).

SR 11302 is an inhibitor of activator protein-1 (AP-1).(In Vitro):SR 11302 can inhibit the growth of breast cancer cell line T-47D, the lung cancer line Calu-6, and HeLa cells. SR 11302 had very little effect on either the proliferation or the differentiation of HL-60, fresh APL, and NB4 cells.(In Vivo):In an AP-1-luciferase transgenic mouse carcinogenesis model, SR11302 significantly inhibits both AP-1 activations in 7,12-dimethyl benz(a)anthracene-initiated mouse skin and 12-O-tetradecanoylphorbol-13-acetate-induced papilloma formation.

SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα. SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells. SR 11302 (SR-11302; 2 μM; 48 hours) inhibits Helicobacter pylori (H. pylori)-induced cell proliferation in adenocarcinoma gastric (AGS) cells.SR 11302 (2 μM; 24 hours) inhibits H. pylori-induced expression of β-catenin and c-myc in AGS cells.

SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr-/- mice in a dose-dependent manner. Animal Model:Vldlr-/- mice Dosage:Low dose 0.5 mg/kg and high dose 1 mg/kg body weight Administration:Orally gavaged daily from P5 to P15 Result:High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight.

——

Cell Cycle/DNA Damage

DNA/RNA Synthesis

11β-HSD1|Gap Junction Protein

——

——

160162-42-5

376.54

C26H32O2

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (66.40 mM)

CC(C=CC=C(C=CC1=C(C)CCCC1(C)C)c1ccc(C)cc1)=CC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years